       Document 0220
 DOCN  M9640220
 TI    Effect of human immunodeficiency virus type 1 infection on the antibody
       response to a glycoprotein conjugate pneumococcal vaccine: results from
       a randomized trial.
 DT    9604
 AU    Ahmed F; Steinhoff MC; Rodriguez-Barradas MC; Hamilton RG; Musher DM;
       Nelson KE; Department of Epidemiology, Johns Hopkins University School
       of; Public Health, Baltimore, MD 21205, USA.
 SO    J Infect Dis. 1996 Jan;173(1):83-90. Unique Identifier : AIDSLINE
       MED/96132467
 AB    Adults (n = 282) were randomized to receive either a pneumococcal
       glycoprotein conjugate vaccine, composed of pneumococcal serotypes 6B,
       14, 18C, 19F, and 23F linked to CRM197, or a 23-valent pneumococcal
       polysaccharide vaccine. Among human immunodeficiency virus
       (HIV)-uninfected persons, conjugate vaccine elicited significantly
       higher IgG antibody geometric mean titers (GMTs) than did polysaccharide
       vaccine for serotypes 6B, 18C, and 23F: IgG GMTs were 9.0 versus 4.8,
       23.2 versus 5.9, and 15.3 versus 4.4 micrograms/mL, respectively. In
       contrast, the two vaccines elicited similar antibody GMTs in
       HIV-infected persons: GMTs ranged from 1.3 to 10.8 micrograms/mL for all
       serotypes. Of note, among persons receiving polysaccharide vaccine,
       antibody GMTs in HIV-uninfected and -infected persons with CD4
       lymphocytes > or = 500/microL were similar. These data underscore the
       importance of controlled clinical evaluations of newer pneumococcal
       vaccines in all high-risk groups for whom pneumococcal immunization is
       recommended and highlight the need for early immunization of
       HIV-infected persons with currently available polysaccharide vaccines.
 DE    Adult  Antibodies, Bacterial/*BIOSYNTHESIS  AIDS-Related Opportunistic
       Infections/PREVENTION & CONTROL  Bacterial Vaccines/*IMMUNOLOGY
       Comparative Study  CD4 Lymphocyte Count  Female
       Glycoproteins/IMMUNOLOGY  Human  HIV Infections/*IMMUNOLOGY  *HIV-1
       IgG/ANALYSIS  Immunization  Male  Pneumococcal Infections/PREVENTION &
       CONTROL  Polysaccharides, Bacterial/IMMUNOLOGY  Streptococcus
       pneumoniae/*IMMUNOLOGY  Support, Non-U.S. Gov't  Support, U.S. Gov't,
       P.H.S.  Vaccines, Conjugate/IMMUNOLOGY  CLINICAL TRIAL  JOURNAL ARTICLE
       MULTICENTER STUDY  RANDOMIZED CONTROLLED TRIAL

       SOURCE: National Library of Medicine.  NOTICE: This material may be
       protected by Copyright Law (Title 17, U.S.Code).

